BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22398969)

  • 21. [Genetic polymorphisms and human sensitivity to pain and opioids].
    Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
    Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients.
    Joly P; Gagnieu MC; Bardel C; Francina A; Pondarre C; Martin C
    Am J Hematol; 2012 May; 87(5):534-6. PubMed ID: 22430884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Environmental and genetic factors associated with morphine response in the postoperative period.
    Coulbault L; Beaussier M; Verstuyft C; Weickmans H; Dubert L; Trégouet D; Descot C; Parc Y; Lienhart A; Jaillon P; Becquemont L
    Clin Pharmacol Ther; 2006 Apr; 79(4):316-24. PubMed ID: 16580900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is maternal opioid use hazardous to breast-fed infants?
    Hendrickson RG; McKeown NJ
    Clin Toxicol (Phila); 2012 Jan; 50(1):1-14. PubMed ID: 22148986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Implausibility of Neonatal Opioid Toxicity from Breastfeeding.
    Zipursky J; Juurlink DN
    Clin Pharmacol Ther; 2020 Nov; 108(5):964-970. PubMed ID: 32378749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
    Susce MT; Murray-Carmichael E; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pain and genetics.
    Fernandez Robles CR; Degnan M; Candiotti KA
    Curr Opin Anaesthesiol; 2012 Aug; 25(4):444-9. PubMed ID: 22732422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk.
    Sainz J; Rudolph A; Hein R; Hoffmeister M; Buch S; von Schönfels W; Hampe J; Schafmayer C; Völzke H; Frank B; Brenner H; Försti A; Hemminki K; Chang-Claude J
    Endocr Relat Cancer; 2011 Apr; 18(2):265-76. PubMed ID: 21317201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety issues of maternal drug therapy during breastfeeding.
    Berlin CM; Paul IM; Vesell ES
    Clin Pharmacol Ther; 2009 Jan; 85(1):20-2. PubMed ID: 19092767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Codeine-related deaths: The role of pharmacogenetics and drug interactions.
    Lam J; Woodall KL; Solbeck P; Ross CJ; Carleton BC; Hayden MR; Koren G; Madadi P
    Forensic Sci Int; 2014 Jun; 239():50-6. PubMed ID: 24747667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global genetic variation of select opiate metabolism genes in self-reported healthy individuals.
    Wendt FR; Pathak G; Sajantila A; Chakraborty R; Budowle B
    Pharmacogenomics J; 2018 Apr; 18(2):281-294. PubMed ID: 28398354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a role for therapeutic drug monitoring with codeine?
    Kelly LE; Madadi P
    Ther Drug Monit; 2012 Jun; 34(3):249-56. PubMed ID: 22569351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
    Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
    Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
    Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
    Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variability and clinical efficacy of morphine.
    Klepstad P; Dale O; Skorpen F; Borchgrevink PC; Kaasa S
    Acta Anaesthesiol Scand; 2005 Aug; 49(7):902-8. PubMed ID: 16045647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.
    Escorial M; Muriel J; Agulló L; Zandonai T; Margarit C; Morales D; Peiró AM
    Minerva Anestesiol; 2024 May; 90(5):386-396. PubMed ID: 38619184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic factors in pain and its treatment.
    Stamer UM; Stüber F
    Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.